The multifunctionality of tumor targeting nanocarriers, that can incorporate gene therapy and targeted small molecules or immunotherapies [103], satisfies the need for cancer-selective checkpoint blockades and a simultaneous knockout of the IL-30 gene, leaving the finely tuned immunological functions of the cytokine and cytokine containing complexes unaltered. The gene discussed is IL27; the disease is cancer.